A5040390930- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Viral Infectious Diseases and Gene Expression in Insects
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Virus-based gene therapy research
- Biosimilars and Bioanalytical Methods
- Immunotherapy and Immune Responses
- Acute Myeloid Leukemia Research
- T-cell and B-cell Immunology
- Silicon Carbide Semiconductor Technologies
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
- Advancements in Semiconductor Devices and Circuit Design
- Integrated Circuits and Semiconductor Failure Analysis
- Multiple Myeloma Research and Treatments
- Nanowire Synthesis and Applications
- Immune cells in cancer
- Diabetes and associated disorders
- Single-cell and spatial transcriptomics
- Biomedical Ethics and Regulation
- Advanced Biosensing Techniques and Applications
Roswell Park Comprehensive Cancer Center
2022-2025
Moffitt Cancer Center
2015-2024
University of South Florida
2016-2023
Vanderbilt University
2014-2019
Clinical Science Institute
2019
Icahn School of Medicine at Mount Sinai
2019
Memorial Sloan Kettering Cancer Center
2009-2018
Cornell University
2018
StemCells (United States)
2017
Kettering University
2013-2014
CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup patients.
CD19 CAR T cell therapy induces complete remissions in 88% of 16 adult patients with relapsed or refractory acute lymphoblastic leukemia.
Five adults with chemotherapy-refractory B-ALL were induced into molecular remissions after treatment CD19 CAR-targeted T cells.
CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution patients remaining in remission after axi-cel LBCL. Prolonged (those occurring at day 30 following infusion) were common >= grade 3 neutropenia seen 21/70 (30-0%) persisting 3/31 (9-7%) 1...
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric adult a number disease states, as 'living drugs,' their toxicity profiles, including cytokine release syndrome (CRS) immune cell-associated neurotoxicity (ICANS), differ markedly from conventional cancer therapeutics. At the time article preparation, US Food Drug Administration (FDA)...
Abstract High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated with chemotherapy. However, it is unknown if this holds for patients axicabtagene ciloleucel (axi-cel), an anti-CD19 targeted chimeric antigen receptor T-cell therapy. The primary objective of retrospective study was to investigate the relationship between MTV and survival (overall [OS] progression-free [PFS]) relapsed/refractory large B-cell (LBCL) axi-cel. Secondary objectives included finding...
Although many adults with B cell acute lymphoblastic leukemia (B-ALL) are induced into remission, most will relapse, underscoring the dire need for novel therapies this disease. We developed murine CD19-specific chimeric antigen receptors (CARs) and an immunocompetent mouse model of B-ALL that recapitulates disease at genetic, cellular, pathologic levels. Mouse T cells transduced all-murine CD3ζ/CD28-based CAR is equivalent to one being used in our clinical trials, eradicate mice mediate...
Chimeric antigen receptors (CARs) have an antigen-binding domain fused to transmembrane, costimulatory, and CD3ζ domains. Two CARs with regulatory approval include a CD28 or 4-1BB costimulatory domain. While both achieve similar clinical outcomes, biologic differences become apparent but not completely understood. Therefore, in this study we aimed identify mechanistic between costimulation that contribute the 2 could be exploited enhance CAR T cell function. Using CD19-targeted cells...
Chimeric antigen receptor (CAR) T-cell therapy is an emerging option for cancer treatment, but its efficacy limited, especially in solid tumors. This partly because the CAR T cells become dysfunctional and exhausted tumor microenvironment. However, key pathways responsible impaired function of remain unclear, which essential to overcome exhaustion.Analysis RNA-sequencing data from CD8+ tumor-infiltrating lymphocytes (TILs) led identification Cbl-b as a potential target. The sequencing were...
Background Co-stimulatory signals regulate the expansion, persistence, and function of chimeric antigen receptor (CAR) T cells. Most studies have focused on co-stimulatory domains CD28 or 4-1BB. CAR cell persistence is enhanced by 4-1BB co-stimulation leading to nuclear factor kappa B (NF-κB) signaling, while resistance exhaustion mutations domain. Methods We hypothesized that a third-generation containing with only PYAP signaling motif (mut06) would provide beneficial aspects both. designed...
Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines therapy. On KarMMa trial, grade ≥ 3 cytopenias and infections were common. We sought to characterize within 100 days ide-cel standard-of-care (SOC) setting. This multi-center retrospective study included 52 patients who received SOC ide-cel; 47 reached day-90 follow-up. Data censored at day 100. Grade cytopenia present among 65% 30 40% 90. Granulocyte colony...